The Pennant Group, Inc.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: US70805E1091
USD
31.11
-0.26 (-0.83%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryPrice Point
High/Low

1Day

52 Week

Valuation
Technical
Day's Volume

CASH

88.88 k

Shareholding (Dec 2025)

FII

25.74%

Held by 88 FIIs

DII

39.66%

Held by 38 DIIs

Promoter

0.00%

How big is The Pennant Group, Inc.?

22-Jun-2025

As of Jun 18, The Pennant Group, Inc. has a market capitalization of 960.73 million, with net sales of 748.17 million and a net profit of 27.80 million over the latest four quarters.

As of Jun 18, The Pennant Group, Inc. has a market capitalization of 960.73 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the company reported net sales of 748.17 million and a net profit of 27.80 million for the latest four quarters.<BR><BR>As of Dec 24, the balance sheet shows shareholder's funds of 293.28 million and total assets of 766.36 million.

View full answer

What does The Pennant Group, Inc. do?

22-Jun-2025

The Pennant Group, Inc. is a holding company that provides healthcare services to seniors in the U.S., with recent net sales of $210 million and a market cap of approximately $960.73 million. Key financial metrics include a P/E ratio of 35.00 and a return on equity of 9.54%.

Overview: <BR>The Pennant Group, Inc. is a holding company that provides healthcare services to the senior population in the United States, operating in the Pharmaceuticals & Biotechnology industry within the micro-cap market.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 210 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 9 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 960.73 Million (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 35.00 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.22 <BR>Return on Equity: 9.54% <BR>Price to Book: 3.16<BR><BR>Contact Details: <BR>Address: 1675 E Riverside Dr Ste 150, EAGLE ID: 83616-7471 <BR>Tel: 1 208 9576025 <BR>Website: https://www.pennantgroup.com/

View full answer

Should I buy, sell or hold The Pennant Group, Inc.?

22-Jun-2025

Who are in the management team of The Pennant Group, Inc.?

22-Jun-2025

As of March 2022, The Pennant Group, Inc.'s management team includes Mr. Daniel Walker as Chairman and CEO, with Mr. Christopher Christensen as a Director and several Independent Directors: Mr. Stephen Covey, Mr. Scott Lamb, Mr. Roderic Lewis, and Dr. John Nackel.

As of March 2022, the management team of The Pennant Group, Inc. includes Mr. Daniel Walker, who serves as the Chairman of the Board and Chief Executive Officer. Additionally, the Board of Directors comprises Mr. Christopher Christensen as a Director, along with several Independent Directors: Mr. Stephen Covey, Mr. Scott Lamb, Mr. Roderic Lewis, and Dr. John Nackel.

View full answer

Is The Pennant Group, Inc. technically bullish or bearish?

23-Sep-2025

As of September 19, 2025, The Pennant Group, Inc. is in a bearish trend, indicated by mixed MACD signals and underperformance against the S&P 500, with a 1-year return of -31.11% compared to the S&P 500's 16.64%.

As of 19 September 2025, the technical trend for The Pennant Group, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength indicated by the weekly MACD being mildly bullish while the monthly MACD is mildly bearish. The Bollinger Bands and KST both show a mildly bearish trend on both weekly and monthly time frames. Daily moving averages also reflect a mildly bearish sentiment. <BR><BR>In terms of performance, the stock has underperformed the S&P 500 across multiple periods, with a 1-year return of -31.11% compared to the S&P 500's 16.64%, and a year-to-date return of -7.32% versus the S&P 500's 13.31%.

View full answer

Is The Pennant Group, Inc. overvalued or undervalued?

21-Oct-2025

As of October 17, 2025, The Pennant Group, Inc. is fairly valued with a P/E ratio of 35 and a PEG ratio of 0.70, but has underperformed with a year-to-date decline of 10.86% compared to the S&P 500's 13.30% gain.

As of 17 October 2025, The Pennant Group, Inc. moved from expensive to fair in its valuation grade. The company is currently fairly valued based on its metrics. Key ratios include a P/E ratio of 35, an EV to EBITDA of 21.52, and a PEG ratio of 0.70, which suggests growth potential relative to its price. In comparison, peers such as Addus HomeCare Corp. have a P/E of 22.05, while Hims & Hers Health, Inc. is considered expensive with a P/E of 54.76.<BR><BR>Despite its fair valuation, The Pennant Group, Inc. has underperformed in recent returns, with a year-to-date decline of 10.86% compared to a 13.30% gain in the S&P 500, and a one-year drop of 32.78% against a 14.08% increase in the index. This performance indicates potential challenges ahead, even as the valuation appears reasonable relative to its peers.

View full answer
iScoreScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Dashboard

1

Low Debt Company with Strong Long Term Fundamental Strength

 
2

With a growth in Net Profit of 42.03%, the company declared Very Positive results in Sep 25

3

With ROCE of 12.90%, it has a attractive valuation with a 3.28 Enterprise value to Capital Employed

4

High Institutional Holdings at 100%

5

Consistent Returns over the last 3 years

stock-summaryMojo Parameters

Mojo Parameters

Stock DNA

stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

USD 1,161 Million (Small Cap)

stock-summary
P/E

35.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.14

stock-summary
Return on Equity

10.40%

stock-summary
Price to Book

3.61

Revenue and Profits:
Net Sales:
289 Million
(Quarterly Results - Dec 2025)
Net Profit:
10 Million
stock-summaryTotal Returns
Total Returns (Price + Dividend) stock-summary
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
6.43%
0%
6.43%
6 Months
24.94%
0%
24.94%
1 Year
28.08%
0%
28.08%
2 Years
57.92%
0%
57.92%
3 Years
129.59%
0%
129.59%
4 Years
86.51%
0%
86.51%
5 Years
-31.2%
0%
-31.2%

The Pennant Group, Inc. for the last several years.

Risk Adjusted Returns v/s stock-summary
stock-summaryNews & Corporate Actions

News

Icon
No Recent News for the Company

Announcements stock-summary

Icon
No announcement available

Corporate Actions stock-summary

Icon
No corporate action available
stock-summaryKey Factors

Quality key factors stock-summary

Factor
Value
Sales Growth (5y)
17.86%
EBIT Growth (5y)
18.62%
EBIT to Interest (avg)
6.96
Debt to EBITDA (avg)
2.88
Net Debt to Equity (avg)
0.22
Sales to Capital Employed (avg)
2.30
Tax Ratio
22.61%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
10.48%
ROE (avg)
9.26%

Valuation key factors

Factor
Value
P/E Ratio
35
Industry P/E
Price to Book Value
3.61
EV to EBIT
25.44
EV to EBITDA
21.77
EV to Capital Employed
3.28
EV to Sales
1.42
PEG Ratio
1.12
Dividend Yield
NA
ROCE (Latest)
12.90%
ROE (Latest)
10.40%

Technicals key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Mildly Bullish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bullish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
Bullish
stock-summary Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
stock-summaryShareholding
Shareholding Snapshot : Dec 2025stock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 58 Schemes (34.6%)

Foreign Institutions

Held by 88 Foreign Institutions (25.74%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summaryFinancial
[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 26.33% vs 4.33% in Sep 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Dec 2025 is 50.72% vs -13.75% in Sep 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Sep'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "289.30",
          "val2": "229.00",
          "chgp": "26.33%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "21.60",
          "val2": "15.30",
          "chgp": "41.18%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "3.30",
          "val2": "1.00",
          "chgp": "230.00%",
          "chgp_class": "negative"
        },
        {
          "field": "Exceptional Items",
          "val1": "-1.70",
          "val2": "-3.10",
          "chgp": "45.16%",
          "chgp_class": "positive"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "10.40",
          "val2": "6.90",
          "chgp": "50.72%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "66.60%",
          "val2": "58.00%",
          "chgp": "0.86%",
          "chgp_class": "positive"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'25",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2025 is 36.32% vs 27.58% in Dec 2024",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2025 is 39.09% vs 74.82% in Dec 2024",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'25",
        "Dec'24",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "947.70",
          "val2": "695.20",
          "chgp": "36.32%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "65.60",
          "val2": "44.30",
          "chgp": "48.08%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "6.70",
          "val2": "7.00",
          "chgp": "-4.29%",
          "chgp_class": "positive"
        },
        {
          "field": "Exceptional Items",
          "val1": "-6.20",
          "val2": "-0.70",
          "chgp": "-785.71%",
          "chgp_class": "negative"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "33.80",
          "val2": "24.30",
          "chgp": "39.09%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "60.20%",
          "val2": "54.90%",
          "chgp": "0.53%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Dec'25 - QoQstock-summary

Dec'25
Sep'25
Change(%)
Net Sales
289.30
229.00
26.33%
Operating Profit (PBDIT) excl Other Income
21.60
15.30
41.18%
Interest
3.30
1.00
230.00%
Exceptional Items
-1.70
-3.10
45.16%
Consolidate Net Profit
10.40
6.90
50.72%
Operating Profit Margin (Excl OI)
66.60%
58.00%
0.86%
USD in Million.
Direction Arrows
Net Sales

QoQ Growth in quarter ended Dec 2025 is 26.33% vs 4.33% in Sep 2025

Direction Arrows
Consolidated Net Profit

QoQ Growth in quarter ended Dec 2025 is 50.72% vs -13.75% in Sep 2025

Annual Results Snapshot (Consolidated) - Dec'25stock-summary

Dec'25
Dec'24
Change(%)
Net Sales
947.70
695.20
36.32%
Operating Profit (PBDIT) excl Other Income
65.60
44.30
48.08%
Interest
6.70
7.00
-4.29%
Exceptional Items
-6.20
-0.70
-785.71%
Consolidate Net Profit
33.80
24.30
39.09%
Operating Profit Margin (Excl OI)
60.20%
54.90%
0.53%
USD in Million.
Direction Arrows
Net Sales

YoY Growth in year ended Dec 2025 is 36.32% vs 27.58% in Dec 2024

Direction Arrows
Consolidated Net Profit

YoY Growth in year ended Dec 2025 is 39.09% vs 74.82% in Dec 2024

stock-summaryCompany CV
About The Pennant Group, Inc. stock-summary
stock-summary
The Pennant Group, Inc.
Pharmaceuticals & Biotechnology
Pennant Group, Inc. is a holding company. The Company through its subsidiaries provides healthcare services to the senior population in the United States. The Company operates home health, hospice and senior living across Arizona, California, Colorado, Idaho, Iowa, Nevada, Oklahoma, Oregon, Texas, Utah, Washington, Wisconsin and Wyoming. It operates through two segments: home health and hospice services and senior living services. It's home health and hospice services segment include its home health, hospice and home care businesses. It provides home health and hospice services through approximately 80 agencies. Senior living services segment includes its assisted living, independent living and memory care communities. It provides assisted living, independent living and memory care services at approximately 54 communities with 3,872 total units.
Company Coordinates stock-summary
Company Details
1675 E Riverside Dr Ste 150 , EAGLE ID : 83616-7471
Registrar Details